{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"96","upperLimit":"168","value":"142"},{"groupId":"OG001","lowerLimit":"96","upperLimit":"145","value":"120"},{"groupId":"OG002","lowerLimit":"144","upperLimit":"216","value":"170"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"131"},{"groupId":"OG001","value":"128"},{"groupId":"OG002","value":"129"}],"units":"Participants"}],"description":"Patients completed diary entries at 6, 12, 24, 48 and 72 hours post dose and then daily up to 7 days post-dose and/or daily until resolution of the flare. Kaplan Meier estimate of time to resolution of gouty flare as reported by patient, along with associated 95% confiedence interval, were reported.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients on this arm received 150 mg subcutaneously (s.c.) at randomization and upon new flare. The doses were provided as pre-filled syringes. The patients were given 3 injections: two placebo and one active drug.","id":"OG000","title":"Canakinumab, Pre-filled Syringes (PFS)"},{"description":"The patients on this arm received 150 mg s.c. at randomization and upon new flare. The doses were provided as lyophilized power and had to be reconstituted with water for injection before application. The patients were given 3 injections: two placebo and one active drug.","id":"OG001","title":"Canakinumab, Lyophilizate (LYO)"},{"description":"The patients on this arm received 40 mg intramuscular (i.m.) at randomization and upon new flare. The patients were given 3 injections: two placebo and one active drug.","id":"OG002","title":"Triamcinolone Acetonide"}],"paramType":"MEDIAN","populationDescription":"Full Analysis Set: The Full Analysis Set (FAS) consisted of all patients as randomized that had at least one dose of study drug. Following the intent-to-treat principle, patients were analyzed according to the treatment they were assigned to at randomization.","reportingStatus":"POSTED","timeFrame":"14 days","title":"Time to Resolution of Gouty Arthritis Flare as Reported by Patient","type":"SECONDARY","unitOfMeasure":"Hours"}